Sankyo Pharma

Daiichi Sankyo is a global pharmaceutical company headquartered in Tokyo, Japan, formed by the 2005 merger of Sankyo and Daiichi Pharmaceutical. The company is a pioneer in oncology, specifically through its proprietary DXd antibody-drug conjugate (ADC) technology, which has led to the development of transformative therapies like Enhertu. Beyond its oncology leadership, Daiichi Sankyo maintains a robust presence in the cardiovascular and specialty medicine markets with products such as the anticoagulant Lixiana. The organization is committed to leveraging its world-class science and technology to create new modalities and innovative medicines for patients with cancer and other diseases with high unmet medical needs. With a significant global footprint, the company collaborates with major partners like AstraZeneca and Merck & Co. to accelerate the delivery of its extensive pipeline.